Catalent, Inc. (NYSE:CTLT) Shares Bought by North Star Asset Management Inc.

North Star Asset Management Inc. raised its holdings in Catalent, Inc. (NYSE:CTLT - Free Report) by 16.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,289 shares of the company's stock after purchasing an additional 14,450 shares during the period. North Star Asset Management Inc. owned 0.06% of Catalent worth $4,506,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of CTLT. CWM LLC lifted its stake in shares of Catalent by 19.7% during the 3rd quarter. CWM LLC now owns 6,113 shares of the company's stock valued at $278,000 after buying an additional 1,005 shares in the last quarter. Kentucky Retirement Systems purchased a new stake in shares of Catalent during the 3rd quarter valued at approximately $664,000. Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in shares of Catalent during the 3rd quarter valued at approximately $296,000. Park Place Capital Corp increased its holdings in Catalent by 25.2% during the 3rd quarter. Park Place Capital Corp now owns 1,533 shares of the company's stock worth $70,000 after acquiring an additional 309 shares during the period. Finally, Exchange Traded Concepts LLC bought a new stake in Catalent during the 3rd quarter worth approximately $31,000.

Wall Street Analyst Weigh In

CTLT has been the topic of a number of analyst reports. StockNews.com initiated coverage on shares of Catalent in a report on Friday. They set a "sell" rating on the stock. Stephens reaffirmed an "equal weight" rating and set a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. Barclays upped their target price on shares of Catalent from $45.00 to $47.00 and gave the stock an "equal weight" rating in a report on Thursday, January 25th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $63.50 target price on shares of Catalent in a report on Tuesday, February 20th. Finally, UBS Group reaffirmed a "neutral" rating and set a $63.50 target price (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $52.46.

Catalent Trading Up 1.0 %

Shares of CTLT stock traded up $0.57 on Monday, hitting $56.05. 1,808,357 shares of the company's stock traded hands, compared to its average volume of 2,569,977. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. Catalent, Inc. has a one year low of $31.45 and a one year high of $60.20. The company's fifty day simple moving average is $56.81 and its 200 day simple moving average is $48.30. The stock has a market capitalization of $10.14 billion, a price-to-earnings ratio of -8.24, a P/E/G ratio of 5.98 and a beta of 1.20.

Catalent (NYSE:CTLT - Get Free Report) last released its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business posted $0.62 EPS. Catalent's revenue for the quarter was down 10.2% on a year-over-year basis. Equities analysts forecast that Catalent, Inc. will post 0.28 EPS for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.